Loading organizations...

§ Private Profile · Providence, RI, USA
Biomedical technology company developing wearable devices for continuous ISF analysis, for biomarker monitoring and early disease detection.
KIFFIK Biomedical, based in Providence, Rhode Island, United States, develops wearable, non-invasive devices for continuous extraction and real-time analysis of interstitial fluid (ISF), an information-rich biofluid. This technology enables biomarker monitoring for early disease detection, particularly in oncology, and supports applications across medical diagnostics, life sciences, and health monitoring, with plans to license its intellectual property. The company has raised $1.33 million in funding and secured a $50 million strategic investment commitment from GEM Group. Employing between 21 and 50 individuals, its leadership includes CEO George Cagna, COO Mr. Marr, and CIO Rene Veloso, with Steve Reindl on the board. KIFFIK Biomedical was founded in 2021. Its business model centers on primarily through IP licensing and securing venture funding, raised $1.33M in unattributed rounds.
KIFFIK Biomedical has raised $20.0M across 1 funding round.
KIFFIK Biomedical has raised $20.0M in total across 1 funding round.
KIFFIK Biomedical has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 30, 2025 | $20M Series A | — | — | Announced |
KIFFIK Biomedical has raised $20.0M in total across 1 funding round.